MX2023007611A - Anticuerpo anti-il1rap. - Google Patents
Anticuerpo anti-il1rap.Info
- Publication number
- MX2023007611A MX2023007611A MX2023007611A MX2023007611A MX2023007611A MX 2023007611 A MX2023007611 A MX 2023007611A MX 2023007611 A MX2023007611 A MX 2023007611A MX 2023007611 A MX2023007611 A MX 2023007611A MX 2023007611 A MX2023007611 A MX 2023007611A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- relates
- polynucleotide
- antigen
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20216926 | 2020-12-23 | ||
| GBGB2105933.2A GB202105933D0 (en) | 2021-04-26 | 2021-04-26 | Anti-IL1rap antibody |
| EP21212368 | 2021-12-03 | ||
| PCT/EP2021/087338 WO2022136569A1 (en) | 2020-12-23 | 2021-12-22 | Anti-il1rap antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007611A true MX2023007611A (es) | 2023-07-12 |
Family
ID=79731073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007611A MX2023007611A (es) | 2020-12-23 | 2021-12-22 | Anticuerpo anti-il1rap. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11479610B2 (https=) |
| EP (1) | EP4267625A1 (https=) |
| JP (1) | JP2024500920A (https=) |
| KR (1) | KR20230123962A (https=) |
| AU (1) | AU2021405730A1 (https=) |
| CA (1) | CA3202942A1 (https=) |
| IL (1) | IL303922A (https=) |
| MX (1) | MX2023007611A (https=) |
| WO (1) | WO2022136569A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020035577A1 (en) | 2018-08-16 | 2020-02-20 | Cantargia Ab | Anti-il1rap antibody compositions |
| EP4267625A1 (en) * | 2020-12-23 | 2023-11-01 | Cantargia AB | Anti-il1rap antibody |
| CA3220913A1 (en) | 2021-05-21 | 2022-11-24 | Leo Pharma A/S | Anti il-1 receptor accessory protein antibodies |
| AR130550A1 (es) | 2022-09-21 | 2024-12-18 | Sanofi Biotechnology | Anticuerpo anti-il-1r3 humanizado y métodos de uso |
| CN116284401B (zh) * | 2023-02-20 | 2024-09-24 | 中国人民解放军军事科学院军事医学研究院 | 人源抗il-1r3抗体及其应用 |
| EP4705340A1 (en) | 2023-05-05 | 2026-03-11 | Otsuka Pharmaceutical Co., Ltd. | Anti-il1rap antibodies |
| CN120775048A (zh) * | 2024-04-02 | 2025-10-14 | 信达生物制药(苏州)有限公司 | 抗il1rap抗体以及其用途 |
| WO2026022232A1 (en) | 2024-07-24 | 2026-01-29 | Almirall, S.A. | Il-1rap inhibitor for treating or preventing hidradenitis suppurativa |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AU2005274905B2 (en) | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| US9403906B2 (en) | 2011-01-19 | 2016-08-02 | Cantargia Ab | Method of treatment of a solid tumor with interleukin-1 accessory protein antibody |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| JP7114460B2 (ja) * | 2015-06-26 | 2022-08-08 | サノフィ・バイオテクノロジー | モノクローナル抗ＩＬ－１ＲＡｃＰ抗体 |
| CA3084459A1 (en) * | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
| AU2018312563A1 (en) | 2017-08-01 | 2020-03-12 | City Of Hope | Anti-IL1RAP antibodies |
| WO2020035577A1 (en) | 2018-08-16 | 2020-02-20 | Cantargia Ab | Anti-il1rap antibody compositions |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| EP4267625A1 (en) * | 2020-12-23 | 2023-11-01 | Cantargia AB | Anti-il1rap antibody |
-
2021
- 2021-12-22 EP EP21844985.8A patent/EP4267625A1/en active Pending
- 2021-12-22 AU AU2021405730A patent/AU2021405730A1/en active Pending
- 2021-12-22 JP JP2023538679A patent/JP2024500920A/ja active Pending
- 2021-12-22 US US17/559,227 patent/US11479610B2/en active Active
- 2021-12-22 WO PCT/EP2021/087338 patent/WO2022136569A1/en not_active Ceased
- 2021-12-22 KR KR1020237020863A patent/KR20230123962A/ko active Pending
- 2021-12-22 IL IL303922A patent/IL303922A/en unknown
- 2021-12-22 MX MX2023007611A patent/MX2023007611A/es unknown
- 2021-12-22 CA CA3202942A patent/CA3202942A1/en active Pending
-
2022
- 2022-06-09 US US17/836,457 patent/US12043666B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3202942A1 (en) | 2022-06-30 |
| IL303922A (en) | 2023-08-01 |
| US12043666B2 (en) | 2024-07-23 |
| KR20230123962A (ko) | 2023-08-24 |
| AU2021405730A1 (en) | 2023-07-06 |
| AU2021405730A9 (en) | 2025-03-20 |
| JP2024500920A (ja) | 2024-01-10 |
| US11479610B2 (en) | 2022-10-25 |
| WO2022136569A1 (en) | 2022-06-30 |
| US20230108007A1 (en) | 2023-04-06 |
| US20220242950A1 (en) | 2022-08-04 |
| EP4267625A1 (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007611A (es) | Anticuerpo anti-il1rap. | |
| JP2010229138A5 (https=) | ||
| WO2022170126A3 (en) | Compounds specific to coronavirus s protein and uses thereof | |
| MX2022008341A (es) | Anticuerpos anti-ccr8 y usos de estos. | |
| MX364874B (es) | Anticuerpos de il-6 y uso de los mismos. | |
| UA96141C2 (ru) | Нейтрализующее антитело, которое имеет специфичность к человеческому il-6 | |
| WO2011066374A3 (en) | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever | |
| MY162024A (en) | Antagonistic human light-specific human monoclonal antibodies | |
| UA98585C2 (uk) | Антитіло, яке специфічно зв'язується з нейропіліном-1 (nrp1) | |
| PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
| ATE403001T1 (de) | Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs | |
| JP2009531283A5 (https=) | ||
| ZA202104912B (en) | Rna encoding a protein | |
| Liu et al. | The mechanism of effective electroacupuncture on T cell response in rats with experimental autoimmune encephalomyelitis | |
| Lewis et al. | Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system | |
| MX2025013209A (es) | Anticuerpos anti-il1rap | |
| MX2023007067A (es) | Proteinas recombinantes de union a cd3 y su uso. | |
| Avouac et al. | Role of stromelysin 2 (matrix metalloproteinase 10) as a novel mediator of vascular remodeling underlying pulmonary hypertension associated with systemic sclerosis | |
| NZ602515A (en) | Proteins that bind pi16 and uses thereof | |
| Zhang et al. | Targeted inhibition of the immunoproteasome blocks endothelial MHC class II antigen presentation to CD4+ T cells in chronic liver injury | |
| NZ591918A (en) | Antibodies to modified human igf-1/e peptides | |
| IL278240B1 (en) | J and their medical/diagnostic uses | |
| Tang et al. | Obstructive sleep apnea-associated hypertensive disorders in pregnancy: a literature review and clinical management strategies | |
| Janodia et al. | Guttate psoriasis following COVID-19 infection | |
| WO2024036204A3 (en) | Modified antibodies and methods of use thereof |